Sun Pharma Share Price: Sun Pharma is set to announce its Q2 FY25 results, with revenue growth expected to be driven by domestic business and higher specialty sales in the US. Gross margins may improve sequentially, though EBITDA margins could decline due to increased R&D spending.
| Subscribe To Our Free Newsletter |
